RecruitingNCT01386437
Immune
Autoimmune polyendocrinopathy type 1
4
studies recruiting now
as of 7 Sept 2026
7
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
17 Feb 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNot applicableNCT07413874
Telehealth Music Therapy for Adults With Endocrine Disorder and Depression
RecruitingNCT04528355
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
RecruitingPhase 2NCT01962415
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Showing the 4 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Autoimmune polyendocrinopathy type 1 studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Autoimmune polyendocrinopathy type 1 study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Autoimmune polyendocrinopathy type 1
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (AIRE).
Treatments being studied
5 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Rivaroxaban (Rivaroxaban accord)
Phase 3Hydroxychloroquine
Phase 2/3Belimumab (Benlysta)
Phase 2Fluvastatin
Phase 2Rituximab (Blitzima)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).